Capricor Therapeutics (CAPR) Non-Current Debt (2013 - 2024)
Capricor Therapeutics' (CAPR) quarterly Non-Current Debt came in at $3.4 million in Q3 2024, little changed year-on-year from $3.4 million in Q4 2023, and little changed quarter-over-quarter from $3.4 million in Q2 2024.
Capricor Therapeutics (CAPR) Non-Current Debt (2013 - 2024) Analysis & Trends
Capricor Therapeutics' Non-Current Debt history runs 12 years deep, the most recent figure standing at $3.4 million for Q3 2024.
- On a quarterly basis, Non-Current Debt changed 0.0% year-over-year to $3.4 million in Q3 2024; TTM through Sep 2024 was $3.4 million, a 0.0% change from a year earlier, with the FY2023 full-year figure at $3.4 million, changed 0.0% from the prior year.
- Non-Current Debt held at $3.4 million in Q3 2024 per CAPR's latest filing, from $3.4 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $3.4 million in Q1 2020 and bottomed at $35469.0 in Q1 2021.
- The 5-year median for Non-Current Debt is $3.4 million (2020), against an average of $2.8 million.
- Across the five-year window, Non-Current Debt plunged 98.95% in 2021 and jumped 9418.9% in 2022, its largest moves.
- Year by year, Non-Current Debt stood at $71471.0 in 2020, then jumped by 4623.96% to $3.4 million in 2021, then changed by 0.0% to $3.4 million in 2022, then changed by 0.0% to $3.4 million in 2023, then changed by 0.0% to $3.4 million in 2024.
- Per Business Quant, the three latest CAPR Non-Current Debt figures stand at $3.4 million (Q3 2024), $3.4 million (Q2 2024), and $3.4 million (Q1 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 105.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 842.92 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Capricor Therapeutics | 1.12 Bn | 1.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 3.38 Mn |
| Jun 30, 2024 | 3.38 Mn |
| Mar 31, 2024 | 3.38 Mn |
| Dec 31, 2023 | 3.38 Mn |
| Sep 30, 2023 | 3.38 Mn |
| Jun 30, 2023 | 3.38 Mn |
| Mar 31, 2023 | 3.38 Mn |
| Dec 31, 2022 | 3.38 Mn |
| Sep 30, 2022 | 3.38 Mn |
| Jun 30, 2022 | 3.38 Mn |
| Mar 31, 2022 | 3.38 Mn |
| Dec 31, 2021 | 3.38 Mn |
| Mar 31, 2021 | 35,469.00 |
| Dec 31, 2020 | 71,471.00 |
| Sep 30, 2020 | 3.38 Mn |
| Jun 30, 2020 | 178,233.00 |
| Mar 31, 2020 | 3.38 Mn |
| Dec 31, 2019 | 3.38 Mn |
| Sep 30, 2019 | 3.38 Mn |
| Jun 30, 2019 | 3.38 Mn |